Safety and efficacy of lorlatinib against...

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma

Abstract

We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.¹.

Authors

Suk Y; Singh SK

Journal

Cell Reports Medicine, Vol. 4, No. 6,

Publisher

Elsevier

Publication Date

June 20, 2023

DOI

10.1016/j.xcrm.2023.101071

ISSN

2666-3791

Associated Experts

Sheila Singh

Professor, Faculty of Health Sciences

Visit profile

Labels